Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.

Christoph NowakMarcus LindZdenek SumnikTerezie PelikanovaLía Nattero-ChavezElena LundbergItxaso RicaMaria A Martínez-BroccaMariSol Ruiz de AdanaJeanette WahlbergRagnar HanasCristina HernandezMaria Clemente-LeónAna Gómez-GilaMarta Ferrer LozanoTheo SasStepanka PruhovaFabricia DietrichSara Puente-MarinUlf HanneliusRosaura CasasJohnny Ludvigsson

Published in: The Journal of clinical endocrinology and metabolism (2022)

Intralymphatic GAD-alum improves glycemic control in recently diagnosed T1D patients carrying HLA DR3-DQ2.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
end stage renal disease
insulin resistance
ejection fraction
newly diagnosed
prognostic factors
editorial comment
metabolic syndrome
patient reported outcomes